certolizumab pegol

Ligand id: 6774

Name: certolizumab pegol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol

No information available.
Summary of Clinical Use
Used to treat rheumatoid arthritis (RA) and Crohn's disease [1]. May also have some effect in related conditions such as axial spondyloarthritis [3]. The EMA granted Europe-wide approval for the use of this drug in patients with RA (moderate to severe, active disease and severe, active and progressive disease), axial spondyloarthritis and psoriatic arthritis in 2009. FDA approval was expanded to include treatment of moderate-to-severe plaque psoriasis, in June 2018.
Mechanism Of Action and Pharmacodynamic Effects
A recombinant Fab' antibody fragment/40kDa polyethylene glycol (PEG2MAL40K) conjugate against TNFα. By neutralising TNFα (soluble and membrane forms), certolizumab pegol disrupts production of pro-inflammatory cytokines such as IL-1β, and this may account for its effectiveness in treating autoimmune conditions such as Crohn's disease [2] and rheumatoid arthritis.
External links